Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
A group of independent FDA advisers voted in favor of OK'ing Pfizer and Celltrion's take on the blockbuster inflammation treatment Remicade for all of the reference drug's approved indications, unswayed by protests from Johnson & Johnson.
Samuel Isaly, co-founder of biotech investment giant OrbiMed Advisors, said biotech's recent dip in valuations will likely start to turn around as Big Pharma--"the guys with cash"--start to swoop in and buy up suddenly affordable assets.
San Diego's Amplyx Pharmaceuticals boosted its Series B fundraise to $49.2 million and expanded its executive ranks, on pace to take its lead antifungal treatment into human trials this year.
Actelion, the standard bearer in treatments for pulmonary arterial hypertension, is scouting for new disease areas as it rolls out its next potential blockbuster, hoping to keep up its pace of growth by pivoting away from its home base.
Sarepta Therapeutics, hoping to win approval with a treatment for Duchenne muscular dystrophy, will have to endure a three-month FDA delay before getting final word on its drug.
Biogen has signed up with a GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.
FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.
Shire's once-rejected treatment for dry eye disease has another date with the FDA, supported by new data the company believes will get the drug on the market and eventually help bring in more than $1 billion in annual revenue.
Bothell, WA-based biotech OncoGenex is laying off nearly a third of its workforce to conserve cash as it holds out hope for its lead cancer program in a move designed to keep the doors open until Phase III results come in.
Osiris Therapeutics CEO Lode Debrabandere is resigning his position after 10 years at the company, citing "personal reasons."